TEAM
CONTACT US
SZ PHARMACEUTICALS
SZ Pharmaceutical: Revolutionizing Wellness with Innovative Therapy
SZ Pharmaceutical is a European pharmaceutical company at the forefront of Wellness innovation. We are pioneering the development of novel treatments using natural cannabinoids, breakthrough compounds for innovative mental health treatments and other breakthrough compounds to address unmet needs in Wellness.
Company Overview
SZ Pharmaceutical is a pharmaceutical company based in Greece, a member of the European Union, and currently subject to clinical trials.

1

European Pharmaceutical Leader
Established pharmaceutical company operating under EU regulations

2

Euro-pacific Operations
Strategic presence in the European pharmaceutical market

3

Innovative Compounds
Development and research of breakthrough pharmaceutical compounds

4

Manufacturing Excellence
Full rights for production, manufacturing, and distribution of medicine and raw materials
THE CEO
Robert Malcom Sapp Jr - Chief Executive Officer
Robert Malcom Sapp Jr CEO.
Early Life and Athletic Foundations
Robert Malcom Sapp Jr. was born on September 22, 1973, in Colorado Springs, Colorado. His remarkable journey from humble beginnings to global icon in sports and entertainment is a testament to his determination and passion. Standing at 6'5" and weighing over 350 pounds, Sapp's physical attributes laid the groundwork for his illustrious career. His athletic prowess began with football, earning him a scholarship to the University of Washington, where he excelled as a standout lineman.
The Transition to Combat Sports
After being drafted by the Chicago Bears, Sapp's football career took an unexpected turn. He shifted his focus to combat sports, marking the birth of "The Beast," a name synonymous with his larger-than-life persona. Sapp quickly gained notoriety in kickboxing and mixed martial arts, captivating fans with his explosive power and undeniable charisma.
Rise to Fame in Japan
Sapp's superstardom reached new heights in Japan, where he became a cultural phenomenon. His fierce battles in the K-1 kickboxing promotion, including legendary fights against Ernesto Hoost, solidified his status as a formidable competitor. His iconic match against Akebono Taro in 2003 drew an astonishing 54 million viewers, cementing his place in history.
Entertainment and Beyond
Beyond the ring, Sapp seamlessly blended his athletic talents with a flair for entertainment. He became a household name in Japan, starring in popular television shows, films, and releasing a pop single. His acting prowess was showcased in films like Elektra and The Longest Yard, while his vibrant personality endeared him to audiences worldwide.
A New Chapter in Medicine and Leadership
In November 2024, Sapp took a monumental step by becoming the CEO of Solomon Zambia Group of Companies. This role allows him to combine his entrepreneurial spirit with his commitment to advancing healthcare. Under his leadership, the company focuses on pharmaceuticals, smart textiles, and international trade, reflecting his vision for innovation and accessibility in healthcare.
Legacy and Impact
Bob Sapp's legacy extends far beyond the ring and screen; he represents resilience, determination, and the pursuit of dreams. He serves as a role model for aspiring athletes and entrepreneurs, demonstrating that one can evolve and adapt, embracing diverse passions along the way. His journey is a powerful reminder that success is not solely defined by victories but also by the impact one makes on the lives of others.
Conclusion
At 51, Bob Sapp stands as a beacon of hope and inspiration, proving that it is never too late to chase one's dreams. His journey from a high school athlete to a global icon in sports and medicine encapsulates the essence of true greatness—one that lies in inspiring others and making a meaningful difference in the world. As "The Beast," he continues to roar, leaving an indelible mark on history.
Best Concierge Award
DECLARATION LETTER

PDF file

DECLARATION LETTER.pdf

6.6 MB

Directors and Their Bio
Anastasia Bezerianou, COO
"Those who don't believe in magic will never find it." ~ Roald Dahl
As a seasoned entrepreneur and business consultant with over two decades of experience, Anastasia Bezerianou has established herself as a visionary leader and strategic thinker. Her distinguished career spans various industries, including business development, operations management, and international trade.
Currently, Anastasia serves as a Board of Directors Member for the Solomon Zambia Group of Companies, a position she has held since November 2024, following the acquisition of the Mentora Development Group of Companies. In this role, she provides invaluable organizational insights and advisory support, driving the group's strategic growth and innovation.
Prior to her current position, Anastasia held key roles at Mentora Development, Single Member P.C., where she served as Chief Operating Officer (COO) from 2020. She was also instrumental in Transform Greece, a subsidiary specializing in real estate and Golden Visa programs. Notably, Anastasia participated as a key team member at the Transform Greece exhibition booth at CES Las Vegas 2023.
Throughout her career, Anastasia has demonstrated her ability to inspire performance through behavioral-based coaching and motivational management techniques. Her talent for strategic decision-making has consistently resulted in exceeding sales targets by 10-30%.
Anastasia received her formal education at Athens University Law School, combining academic knowledge with practical experience to drive business success. Beyond her professional pursuits, she is passionate about volunteering, community involvement, writing, and photography, demonstrating her commitment to personal growth and making a positive impact on society.
Gwendolyn Hubbard, VP of Global Operations
Gwendolyn Hubbard is a trailblazing leader and entrepreneur, born in Lynchburg, Virginia, as the seventh daughter of ten to Reverend Dr. Fletcher Hubbard and Mother Savannah Hubbard. From a young age, Hubbard demonstrated exceptional leadership skills, tutoring her younger siblings and attending to their social and academic development.
Hubbard's impressive career spans over three decades, with 27 honorable years as a Senior Executive in the FBI. She built a people-first culture, delivering business results throughout the intelligence community and leading over 6,000 staff across 56 FBI Field Offices. Hubbard's global expertise includes guiding organizational change, developing and implementing global strategies, and creating common purposes in complex environments.
Currently, Hubbard is the Founder and President of International Oil-Gaz and Mining Services Plus (IOMS Plus), Vice President of RTPC International, a global fish exportation company, and Vice President/Country Director of Baptist Builders International, Inc. (BBI International). She has also launched various humanitarian efforts in Mauritania, focusing on education, transportation, housing, and career development.
Hubbard holds a Bachelor's degree in Business Administration with a minor in Psychology and a Master's Degree in Executive Leadership from Liberty University. She is currently pursuing her Doctoral Degree in Healthcare Management.
With a heart for serving people worldwide, Hubbard continues to inspire and empower individuals, communities, and organizations through her leadership, expertise, and humanitarian efforts.
Dr. Zee (Ezekiel Golan), Chief Innovation Officer
Biohacking Innovator & Entrepreneur, Vancouver, British Columbia, Canada
Results-driven entrepreneur and innovator with a multidisciplinary background in urban agriculture, industrial organic chemistry, applied genetics, bioinformatics, and computer operating system architecture. Proven track record of driving innovation, leading cross-functional teams, and developing intellectual property.
  • Multidisciplinary Project Management
  • Biohacking and Biotechnology
  • Intellectual Property Development
  • Strategic Innovation and Entrepreneurship
Experience:
Clearmind Medicine Special Advisor for Innovation and New Initiatives May 2021 - Present
  • Inventing new compounds, genes, methods, and treatments to expand the company's IP portfolio
  • Providing scientific expertise and advising on experimental design and research questions
Education:
  • Ph.D. in Mathematics, Computational Entomology, and Modelling, The University of Queensland (2007-2012)
  • Mathematics and Computer Science, Technion-Machon Technologi Le'Israel (1992-1996)
  • High School Diploma in Physical Sciences, Handesaim High School (1984-1988)
Calvin Frye, Director of Cannabis and R & D.
As a pioneering Cannabis industry expert, a published author and speaker, my mission is to educate, inspire, and empower audiences through dynamic speaking engagements at conferences. With a passion for destigmatizing Cannabis, promoting its benefits, and fostering meaningful conversations, I aim to shape the future of the industry.
With over two decades of experience in the Cannabis industry, I've had a front-row seat to its evolution. As one of the first legally recognized cannabis businesses in the United States, I've navigated the complexities of legislation, regulation, and advocacy. My experience is rooted in real-world activism, from protesting and promoting fair regulations to ensuring patient access to safe medicine.
As a sought-after speaker, I've traveled the country, keynoting conferences and collaborating with government officials on cannabis regulation. My speaking engagements range from intimate Zoom sessions to keynote addresses, offering a unique, boots-on-the-ground perspective that's often lacking at cannabis events.
With expertise spanning almost every aspect of the cannabis industry, from cultivation to legislation, I'm equipped to speak to audiences at any level of cannabis knowledge. Whether through speaking engagements, joint ventures, or equity partnerships, I'm committed to driving positive change, promoting inclusivity, sustainability, and social equity, and contributing to sound decision-making within the cannabis industry.
For more information about Mr. Frye click this Link http://realcalvinfrye.com
A Powerful Distribution Network
1
Extensive Reach
SZ Pharmaceutical boasts a wide-reaching distribution network across the European Union.
2
Broad Availability
Our products will be stocked in over 40 warehouses and thousands of pharmacies, cosmetic stores, and tobacconists.
3
Market Penetration
This extensive reach provides access to 90% of the relevant market in the country, ensuring wide audience engagement.
4
Multifaceted Promotion
Beyond physical distribution, we leverage exhibitions, influencer marketing, and digital advertising to effectively promote our products.
NEW PHARMACEUTICAL FORMULATIONS & EMA APPROVAL
New Formulations
SZ Pharmaceutical will register new pharmaceutical formulations upon final European Medicines Agency (EMA) approval, creating diversified revenue streams.
EMA Approval
Regulatory approval from the EMA signifies quality and safety, paving the way for market entry and revenue generation.
Market Impact
The registration of "Novel Food" products is projected to yield a valuation of €800M to €1B. Our robust distribution network (40+ warehouses and thousands of retail outlets) reaches 90% of the EU market, ensuring significant audience engagement.
The Future of Wellness
Groundbreaking Compounds
SZ Pharmaceutical focuses on developing novel therapies for overall health conditions using natural cannabinoids, breakthrough compounds for innovative mental health treatments and other groundbreaking compounds. These substances have shown promising results in treating a range of conditions, including pain, cancer, depression, anxiety, and PTSD.
Rigorous Clinical Trials
The company is committed to conducting rigorous clinical trials to ensure the safety and efficacy of its treatments. These trials are designed to evaluate the effectiveness of natural cannabinoids and breakthrough compounds for innovative mental health treatments and other innovative therapies in a controlled setting, providing evidence-based data to support their use.
Building on a Legacy of Innovation

1

Euro Pacific Hellas Heritage
Established in Greece, Euro Pacific Hellas has a long history of success in the pharmaceutical industry, known for its high-quality production and distribution of medicines.

2

Strategic Acquisition
Building on this legacy, SZ Pharmaceutical acquired Euro Pacific Hellas, leveraging its expertise and infrastructure to develop innovative health care treatments.

3

Future-Focused Innovation
SZ Pharmaceutical focuses on developing groundbreaking therapies using natural cannabinoids, breakthrough compounds for innovative mental health treatments and other novel compounds, aiming to revolutionize the treatment of health care conditions.
A Global Network of Expertise
Leading Universities
Strategic Collaboration Set to Revolutionize Medicinal Cannabis Research
SZ Pharmaceutical is proud to announce a groundbreaking partnership with three esteemed Greek institutions: the Medical School of the University of Athens, Aristotle University of Thessaloniki, and the University of Patras. This collaboration aims to pioneer the development of innovative medicinal cannabis products, transforming the pharmaceutical landscape.
A New Era in Medicinal Cannabis Development
By joining forces with these renowned universities, SZ Pharmaceutical seeks to address critical healthcare needs and improve patient outcomes. This partnership will explore various therapeutic applications, including Psychiatry, Oncology, and Pain Management. With a focus on rigorous scientific standards and ethical considerations, SZ Pharmaceutical is committed to prioritizing patient safety and efficacy.
Driving Innovation and Excellence
This cooperation marks a significant milestone in SZ Pharmaceutical's mission to harness the potential of medicinal cannabis for therapeutic use. By leveraging the expertise and resources of these academic partners, SZ Pharmaceutical aims to redefine the possibilities in medicinal cannabis and deliver hope to those in need. Stay tuned for further updates on this transformative journey.
World-Class Researchers
The company collaborates with renowned researchers, such as Dr. Ezekiel Golan, who brings deep knowledge and experience in the field of mental health and breakthrough compounds for innovative mental health treatments. Calvin Frye, a scientist and pioneer in the cannabis industry, also chairs a committee with the National Hemp Association.
International Partnerships
SZ Pharmaceutical seeks to expand its reach and impact through strategic partnerships with global institutions and organizations, fostering collaboration and knowledge exchange in the field of health care research.
A Comprehensive Approach to Overall Health

1

Cannabis-Based Products
The company holds a fully approved medical and recreational cannabis license, enabling the cultivation, production, and distribution of low and high THC products, expanding its portfolio to address a broader spectrum of patient needs.

2

Therapeutic Psychedelics
SZ Pharmaceutical focuses on developing therapeutic applications for breakthrough compounds for innovative mental health treatments, utilizing their potential to address a wide range of mental health conditions, including depression, anxiety, and PTSD.

3

Holistic Treatment
SZ Pharmaceutical believes in a holistic approach to wellness, integrating innovative therapies with traditional treatments and support services to provide comprehensive care for individuals seeking mental well-being.
Building a Better Future for Health Care

1

2

3

1

Accessibility
SZ Pharmaceutical strives to make its treatments accessible to a wider population, ensuring affordability and ease of access to innovative therapies for those seeking health care support.

2

Education and Awareness
The company is committed to raising awareness about health and the potential of natural cannabinoids and breakthrough compounds for innovative mental health therapies, promoting open conversations and reducing stigma associated with these treatments.

3

Empowerment
SZ Pharmaceutical aims to empower individuals to take control of their mental health journey, providing access to evidence-based treatments and resources to support their well-being and recovery.
SZ Pharmaceutical: A Vision for a Wellness Tomorrow

1

SZ Pharmaceutical is a new pharmaceutical company with a clear vision: to revolutionize overall health treatment by developing innovative therapies that leverage the potential of natural cannabinoids, breakthrough compounds for mental health treatments, and other groundbreaking compounds.

2

The company has secured production and distribution rights for several pioneering medicines pending clinical trials, demonstrating its commitment to bringing these treatments to market and making a tangible difference in the lives of those struggling with health conditions.

3

By collaborating with leading universities and researchers, SZ Pharmaceutical is committed to advancing the field of health care research and developing effective therapies that address the growing need for innovative treatment options.
Reaching a Wide Audience
EU Distribution Network
SZ Pharmaceutical products are widely available through a robust network of partners, encompassing pharmacies, cosmetic stores, and tobacconists.
  • 40 Warehouses
  • 10,000-12,000 Pharmacies
  • 2,000-4,000 Cosmetics Stores
  • 20,000 Tobacconists
Marketing and Promotion
A comprehensive marketing strategy ensures broad reach and awareness across diverse channels.
  • Digital Advertising
  • Influencer Marketing
  • Doctor Network
  • Product Promotion
  • Exhibitions and Trade Shows
Targeted Reach
The marketing strategy ensures access to a significant proportion of the target audience.
Direct access to 90% of relevant publications and a strong presence at industry events ensures maximum visibility and impact.
SALES OF RAW MATERIALS AND MANUFACTURING SERVICES
Pharmaceutical Market
SZ Pharmaceutical will supply raw materials and finished products to a large market.
  • Pharmacies
  • Pharmaceutical Companies
  • Medical Institutions
  • Retailers
Healthcare Market
SZ Pharmaceutical will provide products to address a critical need in the Greek healthcare system.
There are 120,000 patients currently waiting for high-THC medicines.
Market Growth
The European and UK markets are projected to grow rapidly.
This represents a significant growth opportunity for SZ Pharmaceutical.
SZ Pharmaceutical: Facilities
44,500
m2
Total facility area
40,000-42,000
kg
Annual production capacity
25,000
m2
Greenhouse space
12,000
m2
Building space
Our 11-acre facility in Karditsa, Greece, boasts a strategic location providing ample room for growth. The facility is comprised of large greenhouses for optimal plant growth and dedicated buildings for processing and packaging, ensuring efficient operations and future expansion to meet demand.
Join Our Journey
SZ Pharmaceutical invites investors, potential partners, and individuals passionate about healthcare innovation to join us on our journey to revolutionize healthcare. Together, we can create a healthier tomorrow.
SZ Pharmaceutical is committed to transparency and open communication with our investors. We regularly provide updates on our progress and financial performance.
For more information get in touch with us @[email protected]
News
Robert Jr Sapp Press Release

PDF file

Bobs Press Release 2.pdf

130.5 KB

Calvin Frye Press Release

PDF file

Calvin's Press Release 1.pdf

54.9 KB

INVESTORS NOTE

1

Risk: Market Saturation
The market may become saturated with competitors if the government issues too many licenses for cannabis or breakthrough compounds for innovative mental health treatment pharmaceuticals. This could lead to increased competition, putting downward pressure on prices and reducing profit margins for all players in the market.

2

Alternatives: Differentiation Strategies
To mitigate the risk of market saturation, SZ Pharmaceutical can focus on several key differentiation strategies. This includes targeting specific niche customer segments with unmet needs, developing unique and innovative product formulations beyond simple psilocybin or MDMA treatments (e.g., exploring combinations or novel delivery methods), and investing heavily in building strong brand loyalty and recognition among both patients and healthcare professionals.

3

Example: The Canadian Cannabis Market
A real-world example of market saturation is the Canadian recreational cannabis market shortly after legalization. The initial wave of licensing led to a flood of producers, resulting in lower-than-expected prices and significant financial challenges for many companies. This highlights the importance of proactive differentiation and strategic planning to navigate a potentially competitive landscape.

4

Risk: Regulatory Uncertainty
Changes in regulations surrounding cannabis and breakthrough compounds for innovative mental health therapies could significantly impact the market. This includes potential shifts in licensing requirements, restrictions on production or distribution, or even a complete reversal of legalization efforts.

5

Alternatives: Regulatory Engagement
SZ Pharmaceutical should actively engage with regulatory bodies, participate in industry discussions, and maintain close monitoring of any changes in the regulatory environment. Proactive engagement can help to shape policy, anticipate challenges, and adapt business strategies accordingly.

6

Example: Shifting Public Opinion
Public opinion on cannabis and breakthrough compounds for innovative mental health therapies can shift over time. A change in public perception, influenced by negative media coverage or evolving scientific understanding, could impact consumer demand and investor confidence.

7

Alternatives: Education and Advocacy
To address shifts in public perception, SZ Pharmaceutical should proactively engage in education and advocacy efforts. This could involve working with patient advocacy groups, supporting research initiatives that demonstrate the safety and efficacy of its products, and engaging in positive media relations to counter misinformation.
Contact Details and Address
SZ Pharmaceutical
Address Ragkava 1, Athens, Greece 10558
Made with Gamma